The FDA's orphan drug designation is a significant regulatory milestone that can lead to increased investor confidence and perceived value in the company's pipeline, potentially accelerating the drug's development and approval process. This designation often results in a positive short-term impact on the stock price due to the enhanced visibility and validation of the company's research efforts.